黄连解胰汤联合AG方案治疗晚期胰腺癌临床疗效的回顾性研究  

Retrospective Study on the Clinical Effect of Huanglian Jieyi Decoction Combined with AG in the Treatment of Advanced Pancreatic Cancer

作　　者：张凤凤 沈梦[1] 李伟[1] 陈凯[1] ZHANG Feng-feng;SHEN Meng;LI Wei;CHEN Kai(Department of Oncology,First Affiliated Hospital of Suzhou University,Suzhou,Jiangsu,215006,China)

机构地区：[1]苏州大学附属第一医院肿瘤科,江苏苏州215006

出　　处：《中国血液流变学杂志》2024年第4期511-515,566,共6页Chinese Journal of Hemorheology

基　　金：国家自然科学基金资助项目(81874454);江苏省中医药科技发展专项(2020ZX20)。

摘　　要：目的探讨黄连解胰汤联合AG化疗方案(吉西他滨及白蛋白结合型紫杉醇)治疗晚期胰腺癌的临床疗效。方法回顾性分析2015年5月—2022年5月在苏州大学附属第一医院进行诊治的96例胰腺癌患者的相关资料,观察组48例,于每个疗程第1、第8天予AG方案(白蛋白结合型紫杉醇125 mg/m^(2)、吉西他滨1000 mg/m^(2))化疗,3周为一个疗程,并在使用西药治疗的同时联合黄连解胰汤口服治疗,1剂/d。采用倾向性评分匹配,纳入仅使用AG方案化疗的患者(对照组)48例。两组患者持续治疗3疗程后,于治疗前后分别收集两组患者的肿瘤指标(CEA、CA199)、系统性炎症指标(NLR、PLR、Glasgow评分),以及实体瘤疗效评价。结果在治疗前,两组患者的肿瘤指标、系统性炎症指标差异均无统计学意义(P>0.05);在治疗后,观察组患者的CEA及CA199水平显著低于对照组;观察组患者治疗后的炎症指标(NLR、PLR、Glasgow评分)水平显著低于对照组,差异均具有统计学意义(P<0.05)。观察组治疗后的疾病控制率(DCR)显著高于对照组,差异具有统计学意义(P<0.05)。结论选用黄连解胰汤联合AG方案化疗可有效降低患者相关肿瘤指标水平、降低患者炎症指标水平,提高患者疾病控制率。Objective To investigate the clinical efficacy of Huanglian Jieyi Decoction combined with AG chemotherapy regimen(gemcitabine and albumin-bound paclitaxel)in the treatment of advanced pancreatic cancer.Methods The relevant data of 96 pancreatic cancer patients treated in the First Affiliated Hospital of Soochow University from May 2015 to May 2022 were retrospectively analyzed.48 cases in the observation group were given AG chemotherapy(albumin-bound paclitaxel 125 mg/m^(2),gemcitabine 1000 mg/m^(2))on the 1st and 8th day of each course.3 weeks for a course of treatment,and the use of Western medicine at the same time combined with Huanglian Jieyi Decoction oral treatment,1 dose/day.With propensity score matching,48 patients(control group)who only used AG chemotherapy were included.After 3 courses of continuous treatment,tumor indicators(CEA,CA199),systemic inflammation indicators(NLR,PLR,Glasgow score)and solid tumor efficacy evaluation were collected before and after treatment.Results Before treatment,there were no significant differences in tumor index and systemic inflammation index between two groups(P>0.05).After treatment,CEA and CA199 levels in observation group were significantly lower than those in control group.The levels of inflammation indicators(NLR,PLR,Glasgow score)after treatment in observation group were significantly lower than those in control group,and the differences were statistically significant(P<0.05).The disease control rate(DCR)after treatment in observation group was significantly higher than that in control group,and the difference was statistically significant(P<0.05).Conclusion The combination of Huanglian Jieyi Decoction and AG chemotherapy can effectively reduce the level of related tumor indicators,reduce the level of inflammation indicators,and improve DCR of patients.

关 键 词：黄连解胰汤 白蛋白结合型紫杉醇 吉西他滨 胰腺癌 

分 类 号：R735.9[医药卫生—肿瘤] R730.52[医药卫生—临床医学]